Novo Nordisk A/S acquires Zaltenibart for $2.1B, targeting rare diseases. NVO shares present a de-risked entry point. Click for this updated look at NVO stock.

Novo Nordisk’s board overhaul signals a decisive return to Foundation-led scientific and operational governance, raising strategic questions about whether the company can sustain U.S. growth and ...

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion. ・The company retired its senior loan ...

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).

Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has been ...

Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards ...

Novo Nordisk shares plunge after semaglutide Alzheimer’s trial fails to meet its main goal, deepening pressure amid ...

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

Novo Nordisk’s closest rival is Eli Lilly, whose GLP-1 drugs have also posted strong demand. A softer read on IRA discounts ...

People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

Shares Danish pharma major Novo Nordisk were down 9.5% at 275.80 kroner today, after it announced disappointing top-line ...

Novo Nordisk will soon announce the results of perhaps the most ambitious studies yet of its GLP-1 drug: whether it can help slow Alzheimer's.